RxDoctor Payments Data

James Harris, NP

Nurse Practitioner · Shreveport, LANPI 1710366570

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $5,024 of the $6,466 with a category attached, or 77.7%. 38 manufacturers reported payments, led by Medtronic at 34.2% of the total. 2025 is the largest year on record at $3,040, 7.8 times the $388 reported in 2021. Among nurse practitioner clinicians in LA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$6,466in general payments, 2019–2025

Across 166 payments — averaging $38.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$619
  • Abiomed$361
  • AstraZeneca$309
  • Neurocrine Biosciences, Inc.$250
  • Pfizer$195
  • plus $3K from 32 others

What the payments were for

  • Travel & lodging$1,44222%
  • Food & beverage$5,02478%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,466 in reported general payments places this provider in the 90th percentile of 969 nurse practitioner providers in Louisiana.

See all nurse practitioner providers in Louisiana

Medicare billing

Part B allowed, 2024
$23,615
Medicare patients
318
Services billed
568

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan45$34,411
EliquisApixaban34$25,067
JardianceEmpagliflozin23$16,010
Metoprolol Succinate70$493
Rosuvastatin Calcium30$435
Ezetimibe24$419
Propafenone Hcl14$386
Atorvastatin Calcium69$317
ClopidogrelClopidogrel Bisulfate38$203
Losartan Potassium30$131
Amlodipine Besylate18$119
Spironolactone28$96
Isosorbide Mononitrate ErIsosorbide Mononitrate25$90
Hydralazine Hcl13$79
Carvedilol17$55

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$146$34,41145 claims
PfizerEliquis$195$25,06734 claims
Boehringer IngelheimJardiance$63$16,01023 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 969 nurse practitioner providers in Louisiana.

Other nurse practitioner in Shreveport

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →